Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Thomas I Wilkes -- 749 2026-07-22 03:30:14 |
2 formatted Perry Fu Meta information modification 749 2026-07-22 04:03:22 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Wilkes, T.I. Biodegradation: A Pharmaceutical Journey. Encyclopedia. Available online: https://encyclopedia.pub/entry/59870 (accessed on 22 July 2026).
Wilkes TI. Biodegradation: A Pharmaceutical Journey. Encyclopedia. Available at: https://encyclopedia.pub/entry/59870. Accessed July 22, 2026.
Wilkes, Thomas I.. "Biodegradation: A Pharmaceutical Journey" Encyclopedia, https://encyclopedia.pub/entry/59870 (accessed July 22, 2026).
Wilkes, T.I. (2026, July 22). Biodegradation: A Pharmaceutical Journey. In Encyclopedia. https://encyclopedia.pub/entry/59870
Wilkes, Thomas I.. "Biodegradation: A Pharmaceutical Journey." Encyclopedia. Web. 22 July, 2026.
Peer Reviewed
Biodegradation: A Pharmaceutical Journey
This is a peer-reviewed entry published in Encyclopedia Journal, full entry can be found at 10.3390/encyclopedia6070159

Pharmaceuticals are essential to modern healthcare but increasingly represent a pervasive and biologically active class of environmental contaminants. Following administration, many drugs are incompletely metabolised in the human body and are excreted as parent compounds or active metabolites, subsequently entering municipal wastewater treatment plants (WWTPs). Conventional treatment processes only partially remove many pharmaceuticals, resulting in chronic sub-therapeutic exposure of microbial communities which act as both functional agents of biodegradation and sensitive ecological targets. Such exposure alters microbial structure and function, reduces biotransformation capacity, promotes the persistence of recalcitrant compounds such as carbamazepine and diclofenac, and drives the selection and dissemination of antibiotic resistance genes. These effects may propagate across aquatic, terrestrial, agricultural, and food systems via treated effluents and biosolids, linking human medical practices to environmental and public health outcomes. By integrating Pharmaceutical science, wastewater engineering, microbiome ecology, and antimicrobial resistance research, this work frames pharmaceutical pollution as a closed-loop OneHealth challenge.

biodegradation drug pathway microbiome pharmaceuticals wastewater treatment
The continuous development of new pharmaceutical compounds is a fundamental requirement for sustaining and advancing global healthcare systems. Escalating challenges such as antimicrobial resistance, the increase in chronic and age-related diseases, and the emergence of novel pathogens necessitate the discovery of drugs with improved efficacy, selectivity, and safety profiles [1][2]. For instance, the declining clinical effectiveness of legacy antibiotics has prompted renewed efforts to identify compounds with novel mechanisms of action, while advances in oncology have driven the development of targeted small-molecule inhibitors and biologics that aim to minimise systemic toxicity [3]. However, despite increasing molecular design and therapeutic targeting, the environmental implications of pharmaceutical use remain insufficiently integrated into early-stage design frameworks and regulatory standards of early drug development [4].
Modern drug development follows a highly regulated and sequential pathway, typically spanning 10–15 years from target identification to post-market surveillance [2]. Following target validation and lead optimisation, candidate compounds undergo extensive pre-clinical testing to evaluate toxicology, pharmacokinetics, and pharmacodynamics [5]. Only a small proportion of these candidates progress into clinical development, which is divided into Phase I (safety and tolerability), Phase II (dose optimisation and preliminary efficacy), and Phase III (large-scale efficacy and safety evaluation) trials prior to regulatory approval [3][6]. However, this standard systematically prioritises clinical endpoints while largely overlooking the downstream environmental fate of pharmaceuticals and their metabolites. Consequently, properties such as persistence, bioaccumulation potential, and ecotoxicity are rarely embedded as primary design constraints.
Following administration, pharmaceuticals are subject to complex absorption, distribution, metabolism, and excretion (ADME) processes that govern both therapeutic bioavailability and elimination pathways. Hepatic metabolism, largely mediated by cytochrome P450 enzyme systems, typically generates more hydrophilic metabolites that facilitate renal or biliary excretion [7]. Nevertheless, many widely prescribed compounds exhibit incomplete metabolism, resulting in the excretion of parent compounds or biologically active metabolites [8][9]. Compounds such as carbamazepine, diclofenac, and ciprofloxacin exemplify this phenomenon, demonstrating high metabolic stability and resistance to biodegradation. These characteristics are intrinsically linked to their physicochemical properties—including aromaticity, halogenation, and structural recalcitrance—which not only impede metabolic transformation but also extend environmental persistence and bioactivity beyond therapeutic contexts.
Upon excretion, pharmaceutical residues enter municipal wastewater systems via multiple pathways, including human excreta, topical wash-off, improper disposal practices, hospital effluents, and industrial discharges [10][11]. Wastewater treatment plants (WWTPs) therefore function as critical control interfaces for the environmental dissemination of pharmaceutical contaminants. However, conventional treatment systems were not designed to target trace organic micropollutants, resulting in highly variable removal efficiencies that depend on compound-specific physicochemical properties and treatment configurations [12][13]. As a result, many pharmaceuticals undergo only partial transformation, leading to their release into surface waters or accumulation in sewage sludge [14].
Within WWTPs, pharmaceutical compounds can actively disrupt biological treatment processes and influence microbial ecosystem dynamics. Antimicrobial and enzyme-inhibitory agents may impair microbial consortia responsible for organic matter degradation, thereby compromising treatment efficiency [15][16]. Furthermore, the partitioning of hydrophobic compounds into biosolids facilitates their transfer to terrestrial systems via sludge application to arable land, thereby extending their environmental footprint [11]. Residual pharmaceuticals have been widely detected in aquatic environments at trace concentrations, where chronic exposure has been associated with sub-lethal effects, including endocrine disruption, behavioural modification, and the propagation of antibiotic resistance determinants [12][17]. These processes illustrate the complex interplay between pharmacological function, environmental persistence, and ecological impact.
Collectively, these observations underscore the necessity of reconceptualising pharmaceutical development within an integrated framework that aligns therapeutic efficacy with environmental sustainability. This work examines the link between pharmaceutical compounds, human metabolism, wastewater treatment processes, and environmental dissemination, situating these interactions within a One Health perspective, with examples from antibiotics, anticonvulsants, antidepressants, beta-blockers, and non-steroidal anti-inflammatory drugs (NSAIDs).

References

  1. Muteeb, G.; Rehman, M.T.; Shahwan, M.; Aatif, M. Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review. Pharmaceuticals 2023, 16, 1615.
  2. FDA. The Drug Development Process; U.S. Food and Drug Administration: Silver Spring, MD, USA, 2018. Available online: https://www.fda.gov (accessed on 4 April 2026).
  3. Wasiullah, M.; Yadav, P.; Maury, S.; Yadav, S.; Yadav, S. Drug development process: A review. Int. J. Pharm. Res. Appl. 2025, 10, 2588–2594.
  4. Cristini, I.; Poluzzi, E.; Soardo, F.; Crisafulli, S.; Polesello, S.; Kirchmayer, U.; Milani, M.; Russo, F.; Nicoletti, M.; Scroccaro, G.; et al. A narrative review on the environmental impact of medicines: From water analysis and in vivo studies to prescribing appropriateness, based on European and Italian legal frameworks. Front. Drug Saf. Regul. 2025, 5, 1681648.
  5. Hughes, J.P.; Rees, S.; Kalindjian, S.B.; Philpott, K.L. Principles of early drug discovery. Br. J. Pharmacol. 2011, 162, 1239–1249.
  6. Almazroo, O.A.; Miah, M.K.; Venkataramanan, R. Drug Metabolism in the Liver. Clin. Liver Dis. 2017, 21, 1–20.
  7. Shah, R. Pharmacokinetics: Drug absorption, distribution, metabolism and excretion. Pharma Innov. J. 2019, 8, 865–869.
  8. Stielow, M.; Witczyńska, A.; Kubryń, N.; Fijałkowski, Ł.; Nowaczyk, J.; Nowaczyk, A. The Bioavailability of Drugs—The Current State of Knowledge. Molecules 2023, 28, 8038.
  9. Arnold, K.E.; Brown, A.R.; Ankley, G.T.; Sumpter, J.P. Medicating the environment: Assessing risks of pharmaceuticalals to wildlife and ecosystems. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 2014, 369, 20130569.
  10. Lunghi, C.; Valetto, M.R.; Caracciolo, A.B.; Bramke, I.; Caroli, S.; Bottoni, P.; Castiglioni, S.; Crisafulli, S.; Cuzzolin, L.; Deambrosis, P.; et al. Call to action: Pharmaceuticalal residues in the environment: Threats to ecosystems and human health. Drug Saf. 2025, 48, 315–320.
  11. Zampelli, S.; Verna, R. Environmental pollution from pharmaceuticalals. Life 2025, 15, 1341.
  12. Ortúzar, M.; Esterhuizen, M.; Olicón-Hernández, D.R.; González-López, J.; Aranda, E. Pharmaceutical Pollution in Aquatic Environments: A Concise Review of Environmental Impacts and Bioremediation Systems. Front. Microbiol. 2022, 13, 869332.
  13. Falås, P.; Wick, A.; Castronovo, S.; Habermacher, J.; Ternes, T.A.; Joss, A. Tracing the limits of organic micropollutant removal in biological wastewater treatment. Water Res. 2016, 95, 240–249.
  14. Almashaqbeh, O.; Emmanouil, C.; Alsalhi, L. Quantification of Pharmaceuticalals in Sludge Produced from Wastewater Treatment Plants in Jordan and Environmental Risk Assessment. Toxics 2026, 14, 62.
  15. Bano, A.; Prasad, B.; Kumari, M.; Meili, L.; Prasad, K.S. Pharmaceuticalals in water and wastewater: Ecological risk and sustainable treatment options. Water Air Soil Pollut. 2025, 236, 516.
  16. Zhang, X.; Yan, S.; Chen, J.; Tyagi, R.D.; Li, J. Physical, chemical, and biological impact (hazard) of hospital wastewater on environment: Presence of pharmaceuticalals, pathogens, and antibiotic-resistance genes. Curr. Dev. Biotechnol. Bioeng. 2020, 79–102.
  17. Gurudiwan, P.; Mire, S.K. Pharmaceuticalals in aquatic environments: Risk assessment and ecological impacts. NESciences 2024, 9, 88–99.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Microbiology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Thomas I. Wilkes
View Times: 6
Online Date: 22 Jul 2026
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback